FILLIF-PEG

Main information

  • Trade name:
  • FILLIF-PEG 6MG/0.6ML
  • Composition:
  • 6MG/0.6ML
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • FILLIF-PEG 6MG/0.6ML
    India
  • Language:
  • English

Other information

Status

  • Source:
  • Central Drugs Standard Control Organization
  • Last update:
  • 09-08-2016

21-9-2018

Pending EC decision:  Jivi, damoctocog alfa pegol, Opinion date: 20-Sep-2018

Pending EC decision: Jivi, damoctocog alfa pegol, Opinion date: 20-Sep-2018

Europe - EMA - European Medicines Agency

21-9-2018

Pending EC decision:  Fulphila, pegfilgrastim, Opinion date: 20-Sep-2018

Pending EC decision: Fulphila, pegfilgrastim, Opinion date: 20-Sep-2018

Europe - EMA - European Medicines Agency

21-9-2018

Pending EC decision:  Pelmeg, pegfilgrastim, Opinion date: 20-Sep-2018

Pending EC decision: Pelmeg, pegfilgrastim, Opinion date: 20-Sep-2018

Europe - EMA - European Medicines Agency

21-9-2018

Pending EC decision:  Ziextenzo, pegfilgrastim, Opinion date: 20-Sep-2018

Pending EC decision: Ziextenzo, pegfilgrastim, Opinion date: 20-Sep-2018

Europe - EMA - European Medicines Agency

27-7-2018

Pending EC decision:  Udenyca, pegfilgrastim, Opinion date: 26-Jul-2018

Pending EC decision: Udenyca, pegfilgrastim, Opinion date: 26-Jul-2018

Europe - EMA - European Medicines Agency

27-7-2018

Pending EC decision:  Pelgraz, pegfilgrastim, Opinion date: 26-Jul-2018

Pending EC decision: Pelgraz, pegfilgrastim, Opinion date: 26-Jul-2018

Europe - EMA - European Medicines Agency

6-7-2018

Expanded Recall: Peg Perego Canada Inc. recalls Various Book Strollers

Expanded Recall: Peg Perego Canada Inc. recalls Various Book Strollers

Health Canada's sampling and evaluation program has determined that these strollers do not meet the Carriages and Strollers Regulations in Canada. Specifically, the strollers do not meet the latching system requirements for folding strollers as they do not have a safety device independent of the latching device to prevent folding.

Health Canada

4-6-2018

FDA approves first biosimilar to Neulasta to help reduce the risk of infection during cancer treatment

FDA approves first biosimilar to Neulasta to help reduce the risk of infection during cancer treatment

FDA approves Fulphila (pegfilgrastim-jmdb) as the first biosimilar to Neulasta (pegfilgrastim) to decrease the chance of infection as suggested by febrile neutropenia in patients with non-myeloid cancer.

FDA - U.S. Food and Drug Administration

24-5-2018

FDA approves a new treatment for PKU, a rare and serious genetic disease

FDA approves a new treatment for PKU, a rare and serious genetic disease

The FDA today approved Palynziq (pegvaliase-pqpz) for adults with a rare and serious genetic disease known as phenylketonuria (PKU).

FDA - U.S. Food and Drug Administration

21-11-2013

Danish Pharmacovigilance Update, 26 September 2013

Danish Pharmacovigilance Update, 26 September 2013

In this issue of Danish Pharmacovigilance Update: Filgrastim (Neupogen) and pegfilgrastim (Neulasta) are associated with risk of capillary leak syndrome.

Danish Medicines Agency

25-9-2018

Udenyca (ERA Consulting GmbH)

Udenyca (ERA Consulting GmbH)

Udenyca (Active substance: pegfilgrastim) - Centralised - Authorisation - Commission Decision (2018)6290 of Tue, 25 Sep 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/004413/0000

Europe -DG Health and Food Safety

25-9-2018

Pelgraz (Accord Healthcare Limited)

Pelgraz (Accord Healthcare Limited)

Pelgraz (Active substance: pegfilgrastim) - Centralised - Authorisation - Commission Decision (2018)6288 of Tue, 25 Sep 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/003961/0000

Europe -DG Health and Food Safety

27-8-2018

Somavert (Pfizer Europe MA EEIG)

Somavert (Pfizer Europe MA EEIG)

Somavert (Active substance: Pegvisomant ) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5684 of Mon, 27 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/000409/T/0087

Europe -DG Health and Food Safety

23-7-2018

Plegridy (Biogen Netherlands B.V.)

Plegridy (Biogen Netherlands B.V.)

Plegridy (Active substance: peginterferon beta-1a) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4881 of Mon, 23 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2827/T/49

Europe -DG Health and Food Safety

5-7-2018

Scientific guideline:  Draft pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance, draft: consultation open

Scientific guideline: Draft pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance, draft: consultation open

This document provides product-specific guidance on the demonstration of the bioequivalence of pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml.

Europe - EMA - European Medicines Agency

29-6-2018

EU/3/18/2035 (Hanmi Europe Limited)

EU/3/18/2035 (Hanmi Europe Limited)

EU/3/18/2035 (Active substance: Efpegsomatropin) - Orphan designation - Commission Decision (2018)4180 of Fri, 29 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/009/18

Europe -DG Health and Food Safety

11-6-2018

Cimzia (UCB Pharma S.A.)

Cimzia (UCB Pharma S.A.)

Cimzia (Active substance: certolizumab pegol ) - Centralised - 2-Monthly update - Commission Decision (2018)3768 of Mon, 11 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1037/II/65

Europe -DG Health and Food Safety

29-5-2018

Withdrawn application:  Fulphila, pegfilgrastim, Initial authorisation

Withdrawn application: Fulphila, pegfilgrastim, Initial authorisation

Europe - EMA - European Medicines Agency

15-5-2018

Lonquex (UAB Sicor Biotech)

Lonquex (UAB Sicor Biotech)

Lonquex (Active substance: lipegfilgrastim) - Centralised - Renewal - Commission Decision (2018)3009 of Tue, 15 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2556/R/39

Europe -DG Health and Food Safety

27-4-2018

Pending EC decision:  Cimzia, certolizumab pegol, Opinion date: 26-Apr-2018

Pending EC decision: Cimzia, certolizumab pegol, Opinion date: 26-Apr-2018

Europe - EMA - European Medicines Agency